Stockscreener 앱 받기
1.32
0.00%
0.00
시장 영업 전:
1.33
0.01
+0.76%
Medicinova Inc 주식(MNOV)의 최신 뉴스
MediciNova Inc (MNOV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MediciNova Inc (MNOV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MediciNova Inc (MNOV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MediciNova Inc (MNOV) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
MediciNova Inc (MNOV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enterprise value to EBIT forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
Price to sales forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
Enterprise value to EBIT forward of MediciNova, Inc. – TSE:4875 - TradingView
MediciNova stock trades steady as investors weigh recent losses and pipeline progress - Ad-hoc-news.de
Price to sales forward of MediciNova, Inc. – TSE:4875 - TradingView
MediciNova stock trades steady as pipeline progress contrasts with lower recent revenues - Ad-hoc-news.de
Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO) - The Globe and Mail
H.C. Wainwright Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MediciNova reaches 200-patient enrollment in ALS study - Investing.com
MediciNova reaches 200-patient enrollment in ALS study By Investing.com - Investing.com Nigeria
ALS patients ineligible for trials join MediciNova's 200-person study - Stock Titan
MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Progress ContinuesOperating Income Trends - DonanımHaber
D Boral Capital maintains MediciNova (MNOV) buy recommendation - MSN
MediciNova Inc outlines its biotech pipeline as investors watch MN-166 progress - Ad-hoc-news.de
Medicinova Inc (MNOV) Holds Steady Near Support After Modest AdvanceFactor Crowding - dars.gov.et
Medicinova Inc (MNOV) Surges 7.6% as Biotech Stock Tests Resistance at $1.49Opening Range Breakout - dars.gov.et
Enterprise value to revenue forward of MediciNova, Inc. – TSE:4875 - TradingView
Price to earnings forward of MediciNova, Inc. – TSE:4875 - TradingView
Enterprise value to EBITDA forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
MediciNova completes patient visits in phase 2 NAFLD trial - Investing.com
MediciNova CEO Provides Shareholder Update - GlobeNewswire
Medicinova Inc (MNOV) Edges Higher: Biotech Stock Tests Resistance After Modest GainPrice Target - dars.gov.et
Medicinova Inc (MNOV) Edges Higher as Stock Holds Above Key SupportIV Spike - dars.gov.et
Medicinova Inc (MNOV) Edges Higher, Holds Above Key Support Amid Low-Volume TradeBPI Reversal - dars.gov.et
MNOV Q1 2026 Earnings: EPS Beat Drives Positive Stock Reaction Despite No RevenueQuarterly Profit Report - dars.gov.et
MediciNova, Inc. Actuals & Estimates (NASDAQ:MNOV) - TradingView
Form 4 MediciNova Inc For: 25 June By Investing.com - Investing.com Nigeria
MediciNova (MNOV) director awarded 44,500 stock options - Stock Titan
MediciNova (MNOV) director Nicole Lemerond receives 44,500 stock options grant - Stock Titan
MediciNova (MNOV) director receives grant of 44,500 stock options - Stock Titan
MediciNova Shareholders Reject Proposal to Increase Authorized Stock - TipRanks
MediciNova (MNOV) 2026 annual meeting voting recap and totals - Stock Titan
Medicinova Inc (MNOV) Holds Near Support Amid Modest DeclineRange Breakout - dars.gov.et
MediciNova Inc (MNOV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MediciNova Inc (MNOV) Institutional Confidence - TradingKey
MediciNova Inc (MNOV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MediciNova: Interview With Founder And CEO Dr. Yuichi Iwaki About The Biotech - Pulse 2.0
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesEBITDA Estimate Trend - newsline.com
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates but Stock Slides on No Revenue UpdateFiscal Year Earnings - dars.gov.et
MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineCore Business Growth - dars.gov.et
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
MediciNova receives U.S. patent allowance for ibudilast combo By Investing.com - Investing.com South Africa
MediciNova receives U.S. patent allowance for ibudilast combo - Investing.com India
MediciNova Receives Notice of Allowance for New Patent - GlobeNewswire
Medicinova Inc (MNOV) Holds Steady, Consolidating Around the $1.31 MarkCovered Call ETF - newsline.com
MediciNova Inc stock (US58468P2038): Nasdaq biotech share edges higher while valuation metrics stay subdued - AD HOC NEWS
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesFinancial Health Score - newsline.com
1.97%
0.83%
자본화:
|
볼륨(24시간):